TREE NEWS reports: Bayer reported third-quarter adjusted EBITDA of €1.62 billion, beating the €1.42 billion market estimate, on sales of €10.05 billion versus €9.89 billion expected. The German group guided full-year adjusted EBITDA to €9.8 billion–€10.3 billion, against a €9.82 billion consensus, and projected negative free cash flow of €500 million–€1.5 billion, compared with an expected negative €1.61 billion.
Bayer Q3 adjusted EBITDA €1.62B beats €1.42B estimate; sales €10.05B
AI take
The headline beat matters less than the mix: Bayer's full-year EBITDA range straddles consensus rather than lifting it, suggesting the quarterly outperformance is not being extrapolated. The more telling line is free cash flow guidance, where the projected outflow is narrower than feared — a signal that cash discipline, not earnings growth, is carrying the story. For RWA and tokenization watchers, Bayer is a reminder that large-cap pharma cash-flow trajectories shape the collateral and credit narratives around real-world assets. Whether the improved cash outlook holds through year-end is the open question.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
15m ago
Yum China Q3 Revenue $3.5B, Adjusted EPS $0.91
16m ago
Country Garden Merges 10 Regional Units Into 6 in Restructuring
22m ago
China’s Rural Retail Sales Reach 6.8 Trillion Yuan in 2025
24m ago
CICC to Take Part in Third Batch of PBOC Swap Facility Operations
37m ago
Russia Confirms Russia-US-Ukraine Talks in Abu Dhabi Nov 10-11
39m ago
Midea Group repurchases 11.757 billion yuan of A-shares through Oct. 31